How are BCMA-directed bispecific antibodies currently utilized in real-world practice for MM?
The Multiple Myeloma Hub was pleased to speak with Hang Quach, St Vincent’s Hospital Melbourne and University of Melbourne, Melbourne, AU. We asked, How are B-cell maturation antigen (BCMA)-directed bispecific antibodies currently utilized in real-world practice for multiple myeloma (MM)?
In this interview, Professor Quach discussed how the development and integration of BCMA-directed bispecific antibodies have transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM). Quach covered regulatory approvals, key clinical trial data, strategies for managing toxicities and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.